Ability of subject to understand and the willingness to sign a written informed consent document. Subjects must be co-enro lled on protocol 03-C-0277. 2.1.2 Exclusion Criteria Pregnant or breastfeeding women who do not consent to stop breastfeeding while on study treatment and for 30 days after the use of the investigational vaccine, where pregnancy is confirmed by a positive, rising hCG laboratory test. Women of child-bearing potential, defined as all women capable of becoming pregnant, unless they agree to use an appropriate me thod of contraception during dosing and for 120 days after the last dose (i.e., final vacci ne). Effective contraception methods include a combination of any two of the following (unless method is abstinence or sterilization, in which only one method is required): x Use of oral, injected, or implanted hormona l methods of contraception, or other forms of hormonal contraception that ha ve comparable efficacy (failure rate < 1%). In case of use of oral contraception, women should have been stable on the same pill for a minimum of 6 months before taking study treatment. xPlacement of an intrauterine device or intrauterine system. x Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal fo am/gel/film/cream/vaginal suppository. x Total abstinence x Female sterilization at least eight weeks before taking study treatment. x Male sterilization (at least six months prior to screening). Abbreviated Title: mRNA-Based, Cancer Vaccine Version Date: January 23, 2019 21 Sexually active males must use a condom dur ing intercourse during dosing and for 120 days after the last dose (i.e., final vaccine), a nd should not father a child in this period. Any systemic steroid therapy or other fo rm of immunosuppressive therapy within 7 days of the first dose of the vaccine. A ph ysiologic dose of systemic corticosteroids may be approve G,QKDOHGRUWRSLFDOVWHURLGVDQG DGUHQDOUHSODFHPHQWVWHURLG GRVHV 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease. Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses of the cardiovascular, respiratory, or immune system.